MultiOmic Health

MultiOmic Health is a London-based AI-enabled drug discovery company focused on metabolic syndrome-related diseases — a cluster of chronic conditions including type 2 diabetes, chronic kidney disease, atherosclerotic cardiovascular disease, and non-alcoholic fatty liver disease. Collectively these conditions account for an estimated $2 trillion in global healthcare costs annually.

The company's proprietary MOHSAIC® platform integrates multi-omics patient data, AI-driven computational systems biology modelling, and targeted wet laboratory experiments to identify distinct patient subpopulations and discover novel precision therapeutic concepts. MultiOmic Health has raised over $8.7 million in seed funding, with its most recent $6.2 million seed extension led by Hoxton Ventures.